Clinical Trial

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.
Protocol Amendment History 586 amendments
This ClinicalTrials.gov record has been amended 586 times since 2005-06-28; most recent amendment 2026-02-06.
Status change: Terminated → Active, Not Recruiting 2019-03-12
Status change: Suspended → Terminated 2016-03-31
Status change: Active, Not Recruiting → Suspended 2011-05-26
Status change: Recruiting → Active, Not Recruiting 2010-10-29
Trial Details
NCT Number NCT00003641
Lead Sponsor ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI), SWOG Cancer Research Network, Cancer and Leukemia Group B, NCIC Clinical Trials Group, Children's Oncology Group
Conditions Melanoma (Skin)
Enrollment 1,150 participants
Start Date 1999-03-25
Primary Completion 2015-01 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-25